异常出血女性子宫内膜癌与子宫内膜上皮内瘤变的风险评估及临床管理算法意义
该研究基于Mayo Clinic前瞻性队列中1163例≥45岁异常出血女性,评估按年龄和子宫内膜厚度分层后的子宫内膜癌及子宫内膜上皮内瘤变绝对风险。结果显示≥60岁者风险最高(17.7%),而<60岁且内膜≤4 mm者风险为0%,提示现有指南推荐与真实风险不一致,按年龄联合内膜厚度分层可提高活检效率。
要点
- ≥60岁异常出血女性子宫内膜癌/内膜上皮内瘤变风险达17.7%,为最高危人群。
- <60岁且内膜厚度≤4 mm者风险为0%,可考虑避免常规活检。
- 推荐对所有≥60岁及<60岁且内膜>4 mm者行活检,效率最高且不漏诊。
核心结论
- 现有异常出血女性子宫内膜癌检测的临床推荐与潜在风险不一致。
- 年龄等风险因素可比复发性出血评估提供更好的风险分层。
研究设计与样本
- 前瞻性临床队列研究,2013年2月至2019年5月从Mayo Clinic纳入1163例≥45岁因异常出血转诊行子宫内膜评估的女性。
主要发现
- 593例绝经后出血女性中,18例(3.0%)为子宫内膜上皮内瘤变,47例(7.9%)为子宫内膜癌。
- 570例绝经前异常出血女性中,8例(1.4%)为子宫内膜上皮内瘤变,7例(1.2%)为子宫内膜癌。
- ≥60岁女性风险最高(17.7%;95%CI 13.0%-22.3%),其次为复发性出血者(14.7%;95%CI 11.0%-18.3%)。
- 初次出血且推荐经阴道超声者中,内膜厚度>4 mm与≤4 mm的风险几乎相同(5.8%;95%CI 1.3%-10.3% vs 3.6%;95%CI 0.9%-8.6%)。
- <60岁且内膜>4 mm者风险为8.4%(95%CI 4.3%-12.5%),≤4 mm者风险为0%(95%CI 0.0%-3.0%;P=.01)。
关键数值与推荐
- 对所有≥60岁女性及<60岁且内膜厚度>4 mm者行活检的策略效率最高,转诊活检比例最低且检测出全部病例。
临床怎么用
- 临床可考虑按年龄(≥60岁)联合内膜厚度(<60岁者>4 mm)分层决定是否行子宫内膜活检,而非仅依据复发性出血或内膜厚度单一指标。
局限性
- 研究纳入单中心转诊人群,结论需在其他人群中验证。
- 未来需正式评估临床与流行病学风险预测模型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most endometrial cancer cases are preceded by abnormal uterine bleeding, offering a potential opportunity for early detection and cure of endometrial cancer. Although clinical guidelines exist for diagnostic workup of abnormal uterine bleeding, consensus is lacking regarding optimal management for women with abnormal bleeding to diagnose endometrial cancer. OBJECTIVE: We report the baseline data from a prospective clinical cohort study of women referred for endometrial evaluation at the Mayo Clinic, designed to evaluate risk stratification in women at increased risk for endometrial cancer. Here, we introduce a risk-based approach to evaluate diagnostic tests and clinical management algorithms in a population of women with abnormal bleeding undergoing endometrial evaluation at the Mayo Clinic. STUDY DESIGN: A total of 1163 women aged ≥45 years were enrolled from February 2013 to May 2019. We evaluated baseline absolute risks and 95% confidence intervals of endometrial cancer and endometrial intraepithelial neoplasia according to clinical algorithms for diagnostic workup of women with postmenopausal bleeding (assessment of initial vs recurrent bleeding episode and endometrial thickness measured through transvaginal ultrasound). We also evaluated risks among women with postmenopausal bleeding according to baseline age (<60 vs 60+ years) as an alternative example. For this approach, biopsy would be conducted for all women aged 60+ years and those aged <60 years with an endometrial thickness of >4 mm. We assessed the clinical efficiency of each strategy by estimating the percentage of women who would be referred for endometrial biopsy, the percentage of cases detected and missed, and the ratio of biopsies per case detected. RESULTS: Among the 593 women with postmenopausal bleeding, 18 (3.0%) had endometrial intraepithelial neoplasia, and 47 (7.9%) had endometrial cancer, and among the 570 premenopausal women with abnormal bleeding, 8 (1.4%) had endometrial intraepithelial neoplasia, and 7 (1.2%) had endometrial cancer. Maximum risk was noted in women aged 60+ years (17.7%; 13.0%-22.3%), followed by those with recurrent bleeding (14.7%; 11.0%-18.3%). Among women with an initial bleeding episode for whom transvaginal ultrasound was recommended, endometrial thickness did not provide meaningful risk stratification: risks of endometrial cancer and endometrial intraepithelial neoplasia were nearly identical in women with an endometrial thickness of >4 mm (5.8%; 1.3%-10.3%) and ≤4 mm (3.6%; 0.9%-8.6%). In contrast, among those aged <60 years with an endometrial thickness of >4 mm, the risk of endometrial cancer and endometrial intraepithelial neoplasia was 8.4% (4.3%-12.5%), and in those with an endometrial thickness of ≤4 mm, the risk was 0% (0.0%-3.0%; P=.01). The most efficient strategy was to perform biopsy in all women aged 60+ years and among those aged <60 years with an endometrial thickness of >4 mm, with the lowest percentage referred to biopsy while still detecting all cases. CONCLUSION: Existing clinical recommendations for endometrial cancer detection in women with abnormal bleeding are not consistent with the underlying risk. Endometrial cancer risk factors such as age can provide important risk stratification compared with the assessment of recurrent bleeding. Future research will include a formal assessment of clinical and epidemiologic risk prediction models in our study population as well as validation of our findings in other populations.
引用
- Clarke MA, Long BJ, Sherman ME, et al. Risk assessment of endometrial cancer and endometrial intraepithelial neoplasia in women with abnormal bleeding and implications for clinical management algorithms. Am J Obstet Gynecol. 2020. PMID: 32268124. doi:10.1016/j.ajog.2020.03.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。